Abbott Laboratories (ABT):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7048
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:211
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Abbott Laboratories (Abbott) develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company’s products comprise specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; nutritional supplements for infants, children and adults; and products for veterinary care. It has research and development, manufacturing and administrative facilities across the world. The company markets its products in North America, Latin America, the Caribbean, the Middle East, Europe, Asia-Pacific and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.

Abbott Laboratories (ABT) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 9
Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Abbott Laboratories, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Abbott Laboratories, Medical Equipment, Deals By Market, 2012 to YTD 2018 13
Abbott Laboratories, Medical Equipment, Deals Summary, 2012 to YTD 2018 14
Abbott Laboratories, Medical Equipment, Deal Details 20
Asset Purchase 20
Abbott Labs Plans to Acquire Medical Optics and Other Products 20
Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For US$56.5 Million 21
Venture Financing 23
Bigfoot Biomedical Raises USD55 Million in Final Tranche of Series B financing 23
Kalila Medical Raises Funds Through Venture Financing 25
Tendyne Raises US$25 Million In Series C Financing 26
Tendyne Raises US$1 Million In Venture Financing 27
Spinal Modulation Raises US$40 Million In Venture Financing 28
Tendyne Raises Additional US$2.6 Million In Venture Financing 29
Nanostim Raises US$9.5 Million In Series C Financing 30
Topera Raises US$25 Million In Series C Financing 31
Spinal Modulation Raises US$2 Million In Venture Financing 32
OptiMedica Raises US$35 Million In Venture Financing 33
Nanostim Raises US$10 Million In Venture Financing 35
Topera Raises US$4 Million In Venture Financing 36
Tendyne Raises US$9 Million In Venture Financing 37
Nanostim Raises US$10 Million In Venture Financing 38
Topera Raises US$2.8 Million In Venture Financing 39
IDev Technologies Raises US$0.83 Million In Venture Financing 40
Private Equity 41
Pharos Capital Group Acquires Majority Stake in TechLab 41
Exponent Private Equity Acquires BBI Diagnostics from Alere for USD162 Million 42
Partnerships 43
Abbott Lab Enters into Licensing Agreement with SurModics 43
Abbott Labs Enters into Licensing Agreement with Beijing Strong Biotechnologies 44
Axis-Shield Enters into Licensing Agreement with Hangzhou Joinstar Biomedical 45
Insulet Extends Licensing Agreement with Abbott Diabetes Care 46
BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 47
Axis-Shield Diagnostic Enters into Licensing Agreement with Siemens Healthcare Diagnostics 48
Robert Bosch Healthcare Systems Enters Into Licensing Agreement With Abbott Diabetes Care 49
Abbott Enters Into Licensing Agreement With Stanford University For Prostate Cancer Biomarkers 50
Insulet Amends Licensing Agreement With Abbott Diabetes 51
Roxwood Medical Enters into Distribution Agreement with Abbott Vascular 52
Abbott Labs and Bigfoot Biomedical Enter into Agreement 53
Akers Biosciences Enters into Distribution Agreement with First Check Diagnostics 54
Celgene and Agios Pharma Enter into Agreement with Abbott Labs 55
Diasend Partners with Abbott Labs 56
MATTER Enters into Agreement with Abbott 57
Abbott Enters into Agreement with GE Healthcare 58
Abbott Labs Enters into Agreement with Sekisui Diagnostics for Coagulation Testing 59
Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 60
Abbott Labs Enters into Co-Development Agreement with US Department of Defense 61
Abbott Molecular Enters into Co-Development Agreement with Biocartis 62
Idera Pharma Enters Into Co-Development Agreement With Abbott Molecular For In Vitro Companion Diagnostic Test 63
Abbott Enters Into Distribution Agreement With R-Pharm For Diabetes Care Products 64
St. Jude Medical Enters Into Distribution Agreement With Spinal Modulation For Axium Neurostimulator System 65
Epizyme Enters Into Co-Development Agreement With Abbott Labs 66
BioGenex Labs Enters Into Co-Marketing Agreement With Abbott Molecular 67
Cellavision Enters Into Distribution Agreement With Abbott 68
Abbott Molecular Enters Into Agreement With Janssen Biotech And Pharmacyclics For Leukemia Test 69
BioView Enters Into Agreement With Abbott To Develop Automated Cancer Screening System 70
Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 71
Alere Enters Into Co-Development Agreement With AT&T 72
Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 73
Abbott Vascular Enters Into Co-Marketing Agreement With St. Jude Medical 74
Abbott Enters Into Co-Development Agreement With Genetics Lab For Molecular Assay Development 75
Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 76
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 77
Equity Offering 78
Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 78
Debt Offering 79
Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 79
Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 80
Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 81
Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 82
Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 84
Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 86
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 88
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 90
Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 92
Alere Raises USD425 Million in Private Placement of 6.37% Notes Due 2023 94
Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 95
Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 96
Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 97
Alere Completes Private Placement Of Notes Due 2020 For US$425 Million 98
St. Jude Medical Completes Public Offering Of Notes Due 2043 For US$700 Million 99
St. Jude Medical Completes Public Offering Of Notes Due 2023 For US$900 Million 101
Alere Completes Private Placement Of Notes Due 2018 For US$450 Million 103
Abbott Completes Private Placement Of Notes Due 2018 For US$1 Billion 104
Abbott Completes Private Placement Of Notes Due 2022 For US$3.1 Billion 105
Abbott Completes Private Placement Of Notes Due 2042 For US$2.6 Billion 106
Abbott Completes Private Placement Of Notes Due 2015 For US$3.5 Billion 107
Abbott Completes Private Placement Of Notes Due 2017 For US$4 Billion 108
Abbott Completes Private Placement Of Notes Due 2015 For US$500 Million 109
Asset Transactions 110
Quidel Acquires Triage and BNP Business from Alere 110
Terumo Acquires Portion of Vascular Closure Portfolio and Other Assets from St. Jude Medical and Abbott Labs for USD1.12 Billion 112
QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 114
Coppersmith Capital Management Reportedly Wants Alere To Explore Sale Of Its Drug Testing And Toxicology Businesses For Up To US$5 Billion 115
Vascular Solutions Acquires Venture Catheter From St. Jude Medical For US$3 Million 116
Acquisition 117
Siemens Healthineers Acquires Epocal from Alere 117
Abbott Labs Acquires Alere 118
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 120
Abbott Labs Acquires St. Jude Medical for up to USD23.6 Billion 121
Abbott Labs Acquires Kalila Medical 123
St. Jude Medical Acquires Thoratec for USD3.3 Billion 124
Abbott Labs Acquires Remaining Stake in Tendyne for USD250 Million 126
Abbott Labs Enters into Option Agreement to Acquire Cephea Valve Technologies 127
Abbott Labs Acquires Omnilab 128
Alere Acquires US Diagnostics USD60 Million 129
St. Jude Medical Acquires Spinal Modulation 130
Abbott Labs Acquires Topera 131
Abbott Labs Receives Right to Acquire Advanced Cardiac Therapeutics 132
Ron Zwanziger Plans to Acquire Alere for USD3.82 Billion 133
Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 134
St. Jude Medical Completes Acquisition of Remaining 81% Stake in CardioMEMS for USD450 Million 135
St. Jude Medical Completes Acquisition Of Nanostim For US$123.5 Million 137
Abbott Laboratories Completes Acquisition Of IDev Technologies 139
Abbott Labs Completes Acquisition Of OptiMedica For Up To USD410 Million 141
St. Jude Medical Acquires Endosense, Developer Of Cardiovascular Devices 143
Alere Completes Acquisition Of Epocal For Up To US$241 Million 145
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 147
Alere Acquires eScreen for USD296 Million 149
Arriva Medical Acquires AmMed Direct For US$23 Million 151
STARLIMS Technologies Acquires Distribution Partners 152
Arriva Medical Acquires Direct Diabetic Source 153
Abbott Laboratories – Key Competitors 154
Abbott Laboratories – Key Employees 155
Abbott Laboratories – Locations And Subsidiaries 157
Head Office 157
Other Locations & Subsidiaries 157
Recent Developments 175
Financial Announcements 175
Jul 18, 2018: Abbott reports second-Quarter 2018 Results 175
Apr 18, 2018: Abbott Reports First-Quarter 2018 Results 178
Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results 181
Oct 18, 2017: Abbott Reports Third-Quarter 2017 Results 184
Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 187
Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 189
Corporate Communications 191
Aug 01, 2018: Global Healthcare Organizations join Abbott to launch the UNIVANTS of Healthcare Excellence Award 191
Sep 22, 2017: Abbott and the Abbott Fund Provide $2 Million in Additional Relief to Help Families Affected by Hurricane Maria and the Earthquake in Central Mexico 192
Sep 18, 2017: Abbott and the Abbott Fund Expand Support for Hurricane Relief With $1 Million to Help Families Affected by Hurricane Irma 193
Sep 07, 2017: Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index 194
Aug 29, 2017: Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts 195
Government and Public Interest 196
Sep 06, 2018: Eighth Annual MedtechVision Conference to Focus on “The Impact of AI on Medicine” 196
Jul 20, 2018: Rapid diagnostics deliver shared value 197
Apr 17, 2018: Battery Performance Alert and Cybersecurity Firmware Updates for Certain Abbott (formerly St. Jude Medical) Implantable Cardiac Devices: FDA Safety Communication 199
Product News 202
Apr 17, 2018: Abbott Releases Planned Updates for Implantable Cardiac Devices 202
Apr 11, 2018: Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease 203
Oct 30, 2017: Analysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease With Xience Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart Surgery 204
Aug 29, 2017: Abbott Issues New Updates for Implanted Cardiac Devices 205
Jul 25, 2017: Abbott Initiates Clinical Trial Of Three-Month Dual Antiplatelet Therapy Following Implantation With Xience Coronary Stent 207
Other Significant Developments 208
Jul 28, 2018: FIND announces new wave of activities to address the challenges threatening hepatitis C elimination through potential diagnostic technologies 208
Jun 19, 2018: ClearStar Expands Medical Testing with Abbott Laboratories Integration 209
Aug 15, 2017: North West London Pathology and Abbott Partner for Diagnostics Products and Services, Including Alinity, in Three NHS Trusts 210
Appendix 211
Methodology 211
About GlobalData 211
Contact Us 211
Disclaimer 211

List of Tables
Abbott Laboratories, Medical Equipment, Key Facts, 2017 2
Abbott Laboratories, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Abbott Laboratories, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Abbott Laboratories, Deals By Market, 2012 to YTD 2018 13
Abbott Laboratories, Medical Equipment, Deals Summary, 2012 to YTD 2018 14
Abbott Labs Plans to Acquire Medical Optics and Other Products 20
Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For US$56.5 Million 21
Bigfoot Biomedical Raises USD55 Million in Final Tranche of Series B financing 23
Kalila Medical Raises Funds Through Venture Financing 25
Tendyne Raises US$25 Million In Series C Financing 26
Tendyne Raises US$1 Million In Venture Financing 27
Spinal Modulation Raises US$40 Million In Venture Financing 28
Tendyne Raises Additional US$2.6 Million In Venture Financing 29
Nanostim Raises US$9.5 Million In Series C Financing 30
Topera Raises US$25 Million In Series C Financing 31
Spinal Modulation Raises US$2 Million In Venture Financing 32
OptiMedica Raises US$35 Million In Venture Financing 33
Nanostim Raises US$10 Million In Venture Financing 35
Topera Raises US$4 Million In Venture Financing 36
Tendyne Raises US$9 Million In Venture Financing 37
Nanostim Raises US$10 Million In Venture Financing 38
Topera Raises US$2.8 Million In Venture Financing 39
IDev Technologies Raises US$0.83 Million In Venture Financing 40
Pharos Capital Group Acquires Majority Stake in TechLab 41
Exponent Private Equity Acquires BBI Diagnostics from Alere for USD162 Million 42
Abbott Lab Enters into Licensing Agreement with SurModics 43
Abbott Labs Enters into Licensing Agreement with Beijing Strong Biotechnologies 44
Axis-Shield Enters into Licensing Agreement with Hangzhou Joinstar Biomedical 45
Insulet Extends Licensing Agreement with Abbott Diabetes Care 46
BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 47
Axis-Shield Diagnostic Enters into Licensing Agreement with Siemens Healthcare Diagnostics 48
Robert Bosch Healthcare Systems Enters Into Licensing Agreement With Abbott Diabetes Care 49
Abbott Enters Into Licensing Agreement With Stanford University For Prostate Cancer Biomarkers 50
Insulet Amends Licensing Agreement With Abbott Diabetes 51
Roxwood Medical Enters into Distribution Agreement with Abbott Vascular 52
Abbott Labs and Bigfoot Biomedical Enter into Agreement 53
Akers Biosciences Enters into Distribution Agreement with First Check Diagnostics 54
Celgene and Agios Pharma Enter into Agreement with Abbott Labs 55
Diasend Partners with Abbott Labs 56
MATTER Enters into Agreement with Abbott 57
Abbott Enters into Agreement with GE Healthcare 58
Abbott Labs Enters into Agreement with Sekisui Diagnostics for Coagulation Testing 59
Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 60
Abbott Labs Enters into Co-Development Agreement with US Department of Defense 61
Abbott Molecular Enters into Co-Development Agreement with Biocartis 62
Idera Pharma Enters Into Co-Development Agreement With Abbott Molecular For In Vitro Companion Diagnostic Test 63
Abbott Enters Into Distribution Agreement With R-Pharm For Diabetes Care Products 64
St. Jude Medical Enters Into Distribution Agreement With Spinal Modulation For Axium Neurostimulator System 65
Epizyme Enters Into Co-Development Agreement With Abbott Labs 66
BioGenex Labs Enters Into Co-Marketing Agreement With Abbott Molecular 67
Cellavision Enters Into Distribution Agreement With Abbott 68
Abbott Molecular Enters Into Agreement With Janssen Biotech And Pharmacyclics For Leukemia Test 69
BioView Enters Into Agreement With Abbott To Develop Automated Cancer Screening System 70
Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 71
Alere Enters Into Co-Development Agreement With AT&T 72
Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 73
Abbott Vascular Enters Into Co-Marketing Agreement With St. Jude Medical 74
Abbott Enters Into Co-Development Agreement With Genetics Lab For Molecular Assay Development 75
Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 76
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 77
Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 78
Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 79
Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 80
Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 81
Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 82
Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 84
Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 86
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 88
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 90
Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 92
Alere Raises USD425 Million in Private Placement of 6.37% Notes Due 2023 94
Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 95
Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 96
Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 97
Alere Completes Private Placement Of Notes Due 2020 For US$425 Million 98
St. Jude Medical Completes Public Offering Of Notes Due 2043 For US$700 Million 99
St. Jude Medical Completes Public Offering Of Notes Due 2023 For US$900 Million 101
Alere Completes Private Placement Of Notes Due 2018 For US$450 Million 103
Abbott Completes Private Placement Of Notes Due 2018 For US$1 Billion 104
Abbott Completes Private Placement Of Notes Due 2022 For US$3.1 Billion 105
Abbott Completes Private Placement Of Notes Due 2042 For US$2.6 Billion 106
Abbott Completes Private Placement Of Notes Due 2015 For US$3.5 Billion 107
Abbott Completes Private Placement Of Notes Due 2017 For US$4 Billion 108
Abbott Completes Private Placement Of Notes Due 2015 For US$500 Million 109
Quidel Acquires Triage and BNP Business from Alere 110
Terumo Acquires Portion of Vascular Closure Portfolio and Other Assets from St. Jude Medical and Abbott Labs for USD1.12 Billion 112
QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 114
Coppersmith Capital Management Reportedly Wants Alere To Explore Sale Of Its Drug Testing And Toxicology Businesses For Up To US$5 Billion 115
Vascular Solutions Acquires Venture Catheter From St. Jude Medical For US$3 Million 116
Siemens Healthineers Acquires Epocal from Alere 117
Abbott Labs Acquires Alere 118
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 120
Abbott Labs Acquires St. Jude Medical for up to USD23.6 Billion 121
Abbott Labs Acquires Kalila Medical 123
St. Jude Medical Acquires Thoratec for USD3.3 Billion 124
Abbott Labs Acquires Remaining Stake in Tendyne for USD250 Million 126
Abbott Labs Enters into Option Agreement to Acquire Cephea Valve Technologies 127
Abbott Labs Acquires Omnilab 128
Alere Acquires US Diagnostics USD60 Million 129
St. Jude Medical Acquires Spinal Modulation 130
Abbott Labs Acquires Topera 131
Abbott Labs Receives Right to Acquire Advanced Cardiac Therapeutics 132
Ron Zwanziger Plans to Acquire Alere for USD3.82 Billion 133
Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 134
St. Jude Medical Completes Acquisition of Remaining 81% Stake in CardioMEMS for USD450 Million 135
St. Jude Medical Completes Acquisition Of Nanostim For US$123.5 Million 137
Abbott Laboratories Completes Acquisition Of IDev Technologies 139
Abbott Labs Completes Acquisition Of OptiMedica For Up To USD410 Million 141
St. Jude Medical Acquires Endosense, Developer Of Cardiovascular Devices 143
Alere Completes Acquisition Of Epocal For Up To US$241 Million 145
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 147
Alere Acquires eScreen for USD296 Million 149
Arriva Medical Acquires AmMed Direct For US$23 Million 151
STARLIMS Technologies Acquires Distribution Partners 152
Arriva Medical Acquires Direct Diabetic Source 153
Abbott Laboratories, Key Competitors 154
Abbott Laboratories, Key Employees 155
Abbott Laboratories, Other Locations 157
Abbott Laboratories, Subsidiaries 157

List of Figures
Abbott Laboratories, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Abbott Laboratories, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Abbott Laboratories, Medical Equipment, Deals by Type, 2012 to YTD 2018 11
Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Abbott Laboratories, Medical Equipment, Deals by Market, 2012 to YTD 2018 13

★海外企業調査レポート[Abbott Laboratories (ABT):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • National Bank Of Bahrain Bsc:企業の戦略・SWOT・財務分析
    National Bank Of Bahrain Bsc - Strategy, SWOT and Corporate Finance Report Summary National Bank Of Bahrain Bsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Grupo Juste SAQF:製薬・医療:M&Aディール及び事業提携情報
    Summary Grupo Juste SAQF (Juste) is a developer and distributor of proprietary medicines and active pharmaceutical ingredients. The company offers oral and injectable radiological contrast media; diatrizoic acid, iothalamic acid, iohexol, iopamidol, iodixanol, MRI contrast agents, dihexazin, and oth …
  • Batu Biologics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Batu Biologics Inc (Batu Biologics) is a biotechnology based pharmaceutical company which develops and commercializes novel cell and gene therapies. Its lead product, ValloVax, a cellular anti-angiogenic cancer vaccine, is developed to induce an immune response against the tumor endothelium …
  • ViroMed Co Ltd (084990):製薬・医療:M&Aディール及び事業提携情報
    Summary ViroMed Co Ltd (ViroMed), formerly ViroMedica Pacific Inc is a biotechnology company that discovers and develops biopharmaceuticals and phytotherapeutics for human diseases. The company provides therapeutic drugs such as therapeutic angiogenesis for cardiovascular diseases, therapeutic cance …
  • Veritas (India) Ltd:企業の戦略・SWOT・財務分析
    Veritas (India) Ltd - Strategy, SWOT and Corporate Finance Report Summary Veritas (India) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Energisa SA (ENGI11):電力:M&Aディール及び事業提携情報
    Summary Energisa SA (Energisa) is a power utility that generates, distributes and sells electricity. The company generates electricity through wind, small hydropower, and biomass resources. It also operates and maintains hydroelectric power plants for other companies; constructs and refurbishes gene …
  • Huntsman Corp (HUN):企業の財務・戦略的SWOT分析
    Huntsman Corp (HUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • SRF Ltd (SRF):企業の財務・戦略的SWOT分析
    SRF Ltd (SRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Thermo Fisher Scientific Inc (TMO):医療機器:M&Aディール及び事業提携情報
    Summary Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of equipment, analytical instruments, reagents and consumables, software and services to tackle complex analytical challenges in research, diagnostics and clinical laboratories. It offers solutions for cellular analysis and biology, …
  • Lycatel Services Ltd:企業の戦略的SWOT分析
    Lycatel Services Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Quidel Corp (QDEL):企業の財務・戦略的SWOT分析
    Quidel Corp (QDEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Cafe De Coral Holdings Limited:企業の戦略・SWOT・財務分析
    Cafe De Coral Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Cafe De Coral Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • RBC Bearings Inc (ROLL):企業の財務・戦略的SWOT分析
    Summary RBC Bearings Inc (RBC Bearings) is an industrial equipment company that manufactures and markets engineered precision bearings and products. The company offers products through industrial and aerospace division. Its industrial products include ball bearings, cam followers, collets and toolho …
  • Micromem Technologies Inc (MRM):企業の財務・戦略的SWOT分析
    Summary Micromem Technologies Inc (Micromem) operates as a technology company that develops and markets magnetic sensor products. The company designs and develops sensors specific to industrial requirements. It offers solutions such as nanoparticle detection solutions, structural integrity sensors, …
  • Sanochemia Pharmazeutika AG (SAC)-医療機器分野:企業M&A・提携分析
    Summary Sanochemia Pharmazeutika AG (Sanochemia) is a specialty pharmaceutical company that develops and manufactures of innovative drugs in selected indication areas such as neurodegeneration, pain and cancer, as well as diagnostic products based on contrast media. The company’s product portfolio i …
  • Fresh Del Monte Produce Inc (FDP):企業の財務・戦略的SWOT分析
    Fresh Del Monte Produce Inc (FDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Petropavlovsk PLC:企業の戦略・SWOT・財務情報
    Petropavlovsk PLC - Strategy, SWOT and Corporate Finance Report Summary Petropavlovsk PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • J. Knipper and Company Inc:企業の戦略的SWOT分析
    J. Knipper and Company Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Innoviva Inc (INVA):企業の財務・戦略的SWOT分析
    Innoviva Inc (INVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • QuantuMDx Group Ltd:医療機器:M&Aディール及び事業提携情報
    Summary QuantuMDx Group Ltd (QuantuMDx) is a developer of sciences tools and diagnostics products. The company’s products include Q-POC, a handheld DNA analyzer that provides an accurate molecular diagnostic results. It develops assays for diagnosis and drug susceptibility testing of infectious dise …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆